Bisoprolol: A Nçw Cardioselective Beta Blocker In Hypertensive Patients
DOI:
https://doi.org/10.47144/phj.v25i1-2.255Keywords:
Bisoprolol, A Nçw Cardioselective Beta Blocker In Hypertensive PatientsAbstract
Introduction:
During sixth decade of this century Beta adrenoceptor antagonists were developed for the treatment of cardiac arrhythmias and angina pectoris. It was discovered later on that long term treatment with beta blockers caused decrease in arterial blood pressure.
Beta adrenergic blocking drugs can be characterized by their pharmacokinetic properties. One property is lipophilic or hydrophilic. Bisoprolol takes an intermediate position between lipophilic and hydrophilic properties of beta blockers. It is readily
Conclusion:
This placebo controlled single blind study of drug monotherapy for patients with uncomplicated mild to moderate essential hypertension demonstrates that Bisoprolol is an effective, well tolerated and safe means of achieving blood pressure in patients with mild to moderate hypertension who have tolerated the drug well with a dose range of 5 to 10 mg. Adverse effects were mostly mild and discontinuation of Bisoprolol therapy was necessary in only 2 (10%) of patients. Patients had good compliance of drug. Therapy because of single drug regimen.
Downloads
Downloads
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/